Rimonabant and depression

Pharmacopsychiatry

Volumn 41, Issue 5, 2008, Pages 204-205

  Soyka, Michael ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RIMONABANT;

ALCOHOLISM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE PREDISPOSITION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HAMILTON ANXIETY SCALE; HAMILTON SCALE; HUMAN; LETTER; MAJOR CLINICAL STUDY; MENTAL DISEASE; PRIORITY JOURNAL; RELAPSE; SUICIDE ATTEMPT;

ALCOHOLISM; ANIMALS; DEPRESSION; HUMANS; PIPERIDINES; PYRAZOLES;

EID: 54749091627     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1078744     Document Type: Letter

References (7)

1. Astrup A, Greenway FL, Ling W et al. Randomized controlled trials of the D1/D5 antagonist ecopipam for weight loss in obese subjects. Obesity 2007; 15: 1717-1731
2. Christensen R, Kruse Kristensen P, Bartels EM et al. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomized trials. Lancet 2007; 370: 1706-1713
3. Colombo G, Orrù A, Lai P, Cabras C, Maccioni P, Rubio M, Gessa GL, Carai MA. The cannabinoid CB1 receptor antagonist, rimonabant, as a promising pharmacotherapy for alcohol dependence: preclinical evidence. Mol Neurobiol 2007; 36: 102-112
4. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959; 32: 50-55
5. Hamilton M. A rating scale of depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62
6. Soyka M, Koller G, Schmidt P et al. Cannabinoid receptor 1 blocker rimonabant (SR 141716) for treatment of alcohol dependence - results from a placebo-controlled double-blind trial. J Clin Psychopharmacol 2008; 3: 317-324
7. US Food and Drug Administration Advisory Committee. FDA briefing document: Zimulti (rimonabant) 20 mg. Rockville: FDA 2007